News

The Phase 1/2 study includes a dose-escalation phase of the study featuring 3 cohorts each one receiving either a low, medium, or high dose of OCU410.

According to the company, the Phase 3 study will have a sample size of 150 participants—one arm of 75 participants with the RHO gene mutation and the other arm with 75 participants that are gene agnostic.

Extended treatment intervals with bevacizumab preserved vision of many patients with high baseline vision.

The 2 organizations to receive initial gifts will be Sight for Life and Eye Corps.

Patients can experience solar retinopathy after viewing the eclipse without protection, but it also can occur from outdoor activities, including those mentioned. It can lead to symptoms that include blurry vision, vision loss at the center of a patient’s sight and eye pain.

NEPTUNE represents the seventh positive Phase 2 study for brepocitinib with more than 1400 subjects and patients treated with brepocitinib in clinical trials. Brepocitinib was generally safe and well-tolerated in the study; no new safety and tolerability signals were identified.

Modern Retina’s interview with Aracelis Torres, PhD, MPH sheds light on how real-world insights empower researchers to see trends and develop new strategies, sometimes even new products, to meet the treatment needs of patients.

Researchers have linked ZIKV to ocular deformities in infants that include retinal lesions, microphthalmia, hemorrhagic retinopathy, retinal pigmented epithelium mottling, optic neuritis and hypoplasia of the optic nerve.

According to the company, EXN407 is the first topical SRPK1 inhibitor to demonstrate both safety and signals of biological response as monotherapy for these indications.

Age-related macular degeneration continues to be a key development area for many pharmaceutical companies as the work to develop new treatment options and present data in the first few months of the year.

The Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine recently received a $1 million donation to drive its efforts to successfully transplant a whole eye.

The effort led to the creation of an artificial vitreous body for treating retinal detachment. This solution is based on a natural carbohydrate derived from algae.

The company announced it has entered into a global licensing agreement with ForSeeCon Eye Corp. for the company's ophthalmology pipeline, which includes the medical device Vitargus.

Research around the globe is working not only to develop treatments for AMD, but also to determine risk factors for the disease to help prevent future cases.

According to Alcon, as CMO, Terry Kim, MD, will continue to integrate scientific and clinical priorities across Alcon’s Surgical and Vision Care franchises, with a focus on meeting the needs of patients and eye care practitioners across the globe.

Nicole Bajic, MD, from the Cole Eye Institute at Cleveland Clinic shares her insights in preparing patients for the 2024 solar eclipse on April 8, 2024.

A total solar eclipse will cross 15 states on April 8, 2024. Durga Borkar, MD, MMCi shares how to communicate eye safety tips and prepare to treat anyone who does present with solar retinopathy.

2024 is already bringing new research and insights to the forefront of retinal vein occlusion and providing new ways to consider retinal vascular health.

Since its US launch in September 2023, more than 40,000 avacincaptad pegol intravitreal solution vials have been distributed to physician practices.

Stargardt disease is the most common inherited retinal dystrophy (causing blurring or loss of central vision) in both adults and children.

The new cohort will add patients living with IRDs caused by mutations in multiple genes to the already existing cohort of patients with IRDs caused by single gene mutations.

In this cohort of 3 adult patients, there was positive safety and efficacy data.

In addition to the primary safety and tolerability endpoints, the study also saw signals of biological response from EXN407

MCO-010 demonstrated a statistically significant improvement of best-corrected visual acuity (BCVA) at week 52.

The European Commission is expected to make a decision about the application before the end of June.

The Phase 2 trial tested whether inhibiting microglia with minocycline might help slow GA expansion and its corresponding vision loss.

The prevalence of AMD features in Republic of Korea Air Force pilots was higher than in other general populations studied.